Abstract 4128
Background
E-health incorporates a range of standards, tools and activities that use electronic to deliver information, resources and services in relation to health care. Final goal is improve quality of health information, strengthening national health systems and ensuring accessible health for population with reduce costs.
Imuno-oncology uses the power of the body’s own immune system to prevent, target, control, and eliminate cancer. Most of Immune related Adverse Events are moderate, reversible if detected early and properly. Teleoncology can decrease the existing gaps between care provider and patients. Allow patients to contact with professionals, permit communication, emotional support, regular assessment and, patient empowerment during and after treatment which rise patient adherence.
Methods
Describe the use of e-health systems to promote cancer care. How e-health technology can improve cancer nurse practise and empower cancer patients receiving Immunotherapy? 3 phases: first literature review searching for e-health nurses interventions with cancer patients in last years. Second; to recruit nurses’ priorities in the 2 countries (Portugal, Spain) to assess and control adherence. Finally a multimodal pathway using e-health technology to provide a checklist for professionals will be develop.
Results
The intended results are to provide a standardized system in order to facilitate the use of e-health, for cancer patients and professionals. Display evidence-based models using a process for framing a question, locating, assessing, evaluating, and repeating it as needed. Is projected to recognize professionals needed skills to improve e-Health technologies to support cancer care, specify e-health interventions for the management of immunotherapy side effects and factors that users perceive or experience as facilitators or barriers to the uptake and implementation of eHealth technologies.
Conclusions
Technology-based interventions could be suitable for immunotherapy treatment. The study will recognize the necessary skills and e-health best system to improve nursing care, adherence and promote quality of life. Further research is required to fully assess the impact of technology as an information and support mechanism for carers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract